Join the 'Hepatitis C' group to help and get support from people like you.

Hepatitis C Blog

Related terms: Hepatitis C, Chronic, Chronic Hepatitis C, Hep C

FDA Approves Viekira Pak (ombitasvir/paritaprevir/ritonavir with dasabuvir) to Treat Hepatitis C

Posted 1 day 9 hours ago by

December 19, 2014 – The U.S. Food and Drug Administration today approved Viekira Pak (ombitasvir, paritaprevir and ritonavir tablets co-packaged with dasabuvir tablets) to treat patients with chronic hepatitis C virus (HCV) genotype 1 infection, including those with a type of advanced liver disease called cirrhosis. Hepatitis C is a viral disease that causes inflammation of the liver that can lead to reduced liver function, liver failure or liver cancer. Most people infected with HCV have no symptoms of the disease until liver damage becomes apparent, which may take decades. According to the Centers for Disease Control and Prevention, about 3.2 million Americans are infected with HCV, and without proper treatment, 15-30 percent of these people will go on to develop cirrhosis. Viekira Pak contains three new drugs—ombitasvir, paritaprevir and dasabuvir—that work together to inhibit the ... Read more

Related support groups: Hepatitis C, Ritonavir

Drug Regimen Cures Hepatitis C in Most Liver Transplant Patients in Study

Posted 16 Nov 2014 by

FRIDAY, Nov. 14, 2014 – A new drug regimen is producing high cure rates in small groups of liver transplant patients with hepatitis C, researchers report. The study's results are a "landmark achievement," said study first author Dr. Paul Kwo, professor of medicine at the Indiana University School of Medicine, in a university news release. "Recurrent hepatitis C post-liver transplantation has historically been difficult to treat, and we have considered post-liver transplant patients a special population in need of new treatment strategies," Kwo said. "What this study showed is that this special population is no longer special. We can treat them as successfully as if they haven't had a liver transplant with drugs that are well tolerated and without risk of rejection," he explained. Kwo said liver transplantation in the United States is mainly the result of cirrhosis – liver scarring – ... Read more

Related support groups: Hepatitis C

FDA Approves Olysio (simeprevir) in Combination with Sofosbuvir for Genotype 1 Chronic Hepatitis C Infection

Posted 5 Nov 2014 by

TITUSVILLE, N.J., Nov. 5, 2014 /PRNewswire/ – Janssen Therapeutics, Division of Janssen Products, LP (Janssen) announced the U.S. Food and Drug Administration (FDA) has approved Olysio (simeprevir), a hepatitis C virus (HCV) NS3/4A protease inhibitor, in combination with sofosbuvir as an all-oral, interferon- and ribavirin-free treatment option for genotype 1 chronic hepatitis C (CHC) infection in adult patients as part of a combination antiviral treatment regimen. Sofosbuvir is an HCV nucleotide analog NS5B polymerase inhibitor developed by Gilead Sciences, Inc. HCV is a blood-born infectious disease of the liver that affects an estimated 3.2 million people in the U.S.[1] Approximately 75 to 85 percent of people who become infected with HCV develop chronic infection.[2] Most persons with CHC infection are asymptomatic, which means they do not show symptoms of the disease.[3] When ... Read more

Related support groups: Hepatitis C, Sovaldi, Sofosbuvir, Olysio, Simeprevir

Vaccine for Hepatitis C Inches Closer to Reality

Posted 5 Nov 2014 by

WEDNESDAY, Nov. 5, 2014 – An initial study suggests that a potential vaccine against hepatitis C, a liver disease that affects at least 130 million people worldwide, is safe in people. The newly released findings are good news, said study co-author Dr. Ellie Barnes, a professor of hepatology and experimental medicine at the University of Oxford in England. The results indicate the vaccine can safely boost the immune system in a way that "targets multiple parts of the hepatitis C virus," she said. "We hope it will have the capacity to prevent people from being infected, and that's something we really need." An estimated 1 percent of U.S. residents have chronic hepatitis C, which is usually transmitted through infected blood. In many people, the disease leads to scarring of the liver – cirrhosis – or liver cancer. A powerful new drug called Sovaldi is expected to improve treatment of ... Read more

Related support groups: Hepatitis C, Vaccination and Prophlaxis

Pricey Hepatitis Drug a Good Bet in U.S. Prisons, Study Says

Posted 20 Oct 2014 by

MONDAY, Oct. 20, 2014 – Using an expensive drug to treat prison inmates with hepatitis C is more cost-effective than another treatment option, according to a new study. More than 500,000 prison inmates in the United States have hepatitis C, which causes liver damage. It's spread by contact with infected blood. The drug Sovaldi (sofosbuvir) costs more than $7,000 a week for 12 weeks of treatment. Some states are concerned about the price and want to limit its use in prisons. However, "it looks like the additional benefits of sofosbuvir are sufficiently large even in this high-risk population to justify its increased cost," study senior author Jeremy Goldhaber-Fiebert, an assistant professor of medicine at the Stanford School of Medicine, said in a university news release. Until a few years ago, hepatitis C patients were treated over 48 weeks with two drugs, pegylated interferon and ... Read more

Related support groups: Hepatitis C, Sovaldi, Sofosbuvir

FDA Approves Harvoni (ledipasvir and sofosbuvir) for Hepatitis C

Posted 14 Oct 2014 by

October 10, 2014 – The U.S. Food and Drug Administration today approved Harvoni (ledipasvir and sofosbuvir) to treat chronic hepatitis C virus (HCV) genotype 1 infection. Harvoni is the first combination pill approved to treat chronic HCV genotype 1 infection. It is also the first approved regimen that does not require administration with interferon or ribavirin, two FDA-approved drugs also used to treat HCV infection. Both drugs in Harvoni interfere with the enzymes needed by HCV to multiply. Sofosbuvir is a previously approved HCV drug marketed under the brand name Sovaldi. Harvoni also contains a new drug called ledipasvir. “With the development and approval of new treatments for hepatitis C virus, we are changing the treatment paradigm for Americans living with the disease,” said Edward Cox, M.D., M.P.H., director of the Office of Antimicrobial Products in the FDA’s Center for Dr ... Read more

Related support groups: Hepatitis C, Sofosbuvir

Hepatitis C Could Become Rare Disease in 20 Years: Study

Posted 4 Aug 2014 by

MONDAY, Aug. 4, 2014 – The once tough-to-treat liver infection hepatitis C could become a rare disease in the United States in the next two decades, a new study estimates. Hepatitis C, a viral infection that harms the liver, is usually passed through infected blood. For most people, the infection becomes chronic and it can eventually lead to scarring of the liver (cirrhosis) or liver cancer. U.S. health officials estimate that over 3 million Americans currently have chronic hepatitis C – most of whom don't know it because the infection usually causes no symptoms. But with recent treatment advances, hepatitis C could become rare by 2036, researchers report in the Aug. 5 issue of the Annals of Internal Medicine. "Rare" refers to a disease that affects one in 1,500 people at most, said senior researcher Jagpreet Chhatwal, who conducted the study while at the University of Pittsburgh ... Read more

Related support groups: Hepatitis C, Sovaldi, Sofosbuvir

HIV Meds May Also Help Control Hepatitis C, Study Finds

Posted 23 Jul 2014 by

WEDNESDAY, July 23, 2014 – For patients infected with both HIV and hepatitis C, HIV antiretroviral therapy may help control both viruses, a small study suggests. Researchers said doctors could use their findings to improve treatment strategies for people with the two diseases. "The findings suggest that HIV suppression with antiretroviral medications plays an important role in the management of individuals with [hepatitis C] and HIV infection," said study leader Dr. Kenneth Sherman, a professor of medicine at the University of Cincinnati College of Medicine. "It supports the concept that in those with HCV/HIV infection, early and uninterrupted HIV therapy is a critical part of preventing liver disease." The researchers conducted the study to address concerns that treating patients who have HIV – the AIDS-causing virus – and hepatitis C with HIV antiretroviral therapy would damage the ... Read more

Related support groups: Hepatitis C, HIV Infection

Hepatitis C Infection May Have 'Silver Lining' for Transplant Patients

Posted 25 Jun 2014 by

WEDNESDAY, June 25, 2014 – The liver-damaging hepatitis C virus may come with an unexpected benefit for patients who need a liver transplant due to the infection, a new European study reports. The virus appears to restrain a dangerous immune system response that can otherwise cause the body to reject the new liver, according to findings published June 25 in Science Translational Medicine. This effect allowed about half of a small group of liver transplant patients to stop taking drugs that suppress their immune system, said lead author Felix Bohne, a postdoctoral fellow with the Institute of Virology at the Technical University of Munich Hemholtz Center Munich, Germany. "It is always a hard thing to translate results from clinical studies into the everyday treatment of patients, but our study clearly shows that hepatitis C-infected liver recipients can discontinue the immunosuppressive ... Read more

Related support groups: Hepatitis C, Organ Transplant

Alcohol Fuels Liver Disease in Those With HIV and Hepatitis C

Posted 7 May 2014 by

WEDNESDAY, May 7, 2014 – People infected with both HIV and hepatitis C are much more likely to develop advanced liver disease if they drink any alcohol at all, according to a new study. Researchers analyzed data from thousands of participants in a Veterans Affairs study on aging and found the risk of advanced liver fibrosis increased overall with alcohol use but was especially striking in patients with both HIV and hepatitis C (co-infected patients). The data included more than 700 people who were infected with both HIV and hepatitis C, more than 1,400 infected with HIV only, nearly 300 infected with hepatitis C only, and nearly 1,160 uninfected people. Among the study participants who were light drinkers, co-infected patients were 13 times more likely than non-infected people to have advanced liver fibrosis. Among participants who were heavy drinkers, co-infected patients were 21 ... Read more

Related support groups: Hepatitis C, HIV Infection, Liver and Pancreatic Disease, Alcoholic Liver Damage, Acute Alcohol Intoxication

Cure Rate for Experimental Hepatitis C Drug Tops 95 Percent

Posted 10 Apr 2014 by

THURSDAY, April 10, 2014 – Researchers report that an experimental drug has cured more than 95 percent of patients infected with hepatitis C, including some who failed other treatments. If it wins approval from the U.S. Food and Drug Administration, this new drug, called ABT-450, could potentially compete with another innovative hepatitis C medication that costs $1,000 a day. Nearly 3 million Americans have hepatitis C, a disease that can cause liver cirrhosis and cancer. These newer, advanced treatments are better-tolerated and easier to take than interferon, the traditional standard treatment for hepatitis C, researchers say. "Interferon is no longer required to cure hepatitis C," said Dr. Stefan Zeuzem, a professor of medicine at the J.W. Goethe University Hospital in Frankfurt, Germany, and lead researcher on the ABT-450 study. His research pairing ABT-450 with other ... Read more

Related support groups: Hepatitis C

Hepatitis C Patients With HIV May Face Higher Risk of Liver Disease

Posted 19 Mar 2014 by

WEDNESDAY, March 19, 2014 – Among people with hepatitis C, the risk of serious liver disease is much higher in those who also have HIV than in those without the AIDS-causing virus, a new study finds. This is true even among patients with HIV who are otherwise benefiting from antiretroviral therapy to treat the virus, the University of Pennsylvania researchers said. They analyzed data from more than 4,200 patients with both hepatitis C and HIV who were receiving antiretroviral therapy. In addition, they looked at data on more than 6,000 patients with hepatitis C only. The patients received care between 1997 and 2010. The HIV/hepatitis C patients had an 80 percent higher rate of serious liver disease than those with hepatitis C only, according to the study, which was published in the March 18 issue of the journal Annals of Internal Medicine. Even HIV/hepatitis C patients who had a good ... Read more

Related support groups: Hepatitis C, HIV Infection

Nearly 3 Million Americans Living With Hepatitis C

Posted 3 Mar 2014 by

MONDAY, March 3, 2014 – More than 2.7 million Americans are currently infected with liver-damaging hepatitis C, federal officials say, and one expert believes that number could be even higher. These individuals are at much higher risk for liver disease, liver cancer and other chronic health issues, experts note. And although there are treatments available that can rid the body of the virus, many Americans remain unaware that they are even infected, according to researchers from the U.S. Centers for Disease Control and Prevention. The long-term consequences of not diagnosing and treating hepatitis C are dire: Experts say more people in the United States now die from infection with hepatitis C than from HIV, the virus that causes AIDS. The new survey of U.S. households, which took place between 2003 and 2010, found the number of people living with hepatitis C has actually fallen by ... Read more

Related support groups: Hepatitis C

Most With Hepatitis C May Soon Find Hope in New Treatments

Posted 15 Jan 2014 by

WEDNESDAY, Jan. 15, 2014 – Hepatitis C treatment isn't pretty, but the dark days of weekly injections, rough side effects and no guarantee of full recovery from the liver-damaging disease may soon be over, researchers report. Two studies, both published in the Jan. 16 issue of the New England Journal of Medicine, involved giving various combinations of antiviral pill cocktails to patients with hepatitis C. Some had failed to respond to standard treatments, and some had not received treatment yet. Yet, the cocktails cleared the virus in both studies for between 93 percent and 98 percent of the patients. These cocktails are game-changers for the illness, said Andrew Muir, director of gastroenterology and hepatology research at the Duke Clinical Research Institute. "This has made me change the way I'm talking with patients. These regimens are essentially going to cure everybody," said ... Read more

Related support groups: Hepatitis C, Sovaldi, Sofosbuvir

Sovaldi Approved for Chronic Hepatitis C

Posted 9 Dec 2013 by

MONDAY, Dec. 9, 2013 – Sovaldi (sofosbuvir) has been approved by the U.S. Food and Drug Administration to treat chronic infection with Hepatitis C. It's considered a breakthrough medication since it's the first such drug that does not require same-time administration of interferon, the agency said in a news release. Infection with the hepatitis C virus causes liver inflammation that can lead to liver failure. Most infected people have no symptoms for years until the onset of liver failure, the FDA said. Complications may include a yellowing of the eyes and skin called jaundice, liver cancer, bleeding or fluid accumulation in the abdomen. Some 3.2 million Americans are infected with hepatitis C, the agency said. Sovaldi is designed to inhibit a protein that the virus needs to replicate. The drug's safety and effectiveness were evaluated in clinical studies involving 1,947 people who ... Read more

Related support groups: Hepatitis C

Page 1 2 3 4 5 6 7 Next

Ask a Question

Further Information

Related Condition Support Groups

Infectious Hepatitis

Related Drug Support Groups

Incivek, ribavirin, Sovaldi, Pegasys, Victrelis, PegIntron, interferon alfa-2b, Ribasphere, Copegus, view more... telaprevir, Harvoni, Rebetol, Olysio, interferon alfa-2a, peginterferon alfa-2b, boceprevir, interferon alfa-2b / ribavirin, sofosbuvir, Intron A, peginterferon alfa-2a, RibaPak, simeprevir, Roferon-A, Rebetron, Infergen, interferon alfacon-1, ledipasvir / sofosbuvir, RibaTab